Clene Inc.
CLNN
Jodie situation report
CLNN dominates a concentrated Gene Therapies move.
CLNN accounts for 45.9% of the group's measured movement across 3.7 effective names. raw member direction is mixed; 5 of 8 SPY-adjusted paths align to the upside. Capital-flow agreement is 18%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
CLNN was the first measured mover. CLNN crossed its material path threshold at 15:35 ET. PACB, BCDA, DNA followed.
5 of 8 members in Gene Therapies are active. No disclosed relationship network is available for this name; the confirmation read above is market-derived.
- Participation spreads to CLNN, PACB, VERU.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as PRTA begins moving with the group.
Invalidation: The live read weakens if participation falls to 2 of 8 members or fewer.
Who this business touches
The relationships behind CLNN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CLNN is currently a Participant in the organic co-movement group Gene Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. No verified filing-linked names are available yet.